Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 13/20 | 0.42 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3947968 | 0.89 | KIT (0.44) | KITEGFRKDRRETENPP1 | |
| SCHEMBL3954372 | 0.85 | EHMT2 (0.52) | KITEGFRKDRAURKBAURKA | |
| SCHEMBL3952952 | 0.85 | AURKA (0.51) | EGFRKDRAURKBAURKA | |
| Hydrochloric Acid SCHEMBL2191376 | 0.84 | AURKA (0.51) | EGFRKDRAURKBAURKA | |
| SCHEMBL17780901 | 0.74 | KIT (0.61) | KITEGFRKDRRETENPP1 | |
| SCHEMBL29803040 | 0.72 | CYP3A4 (0.60) | CYP3A4TDP1 | |
| SCHEMBL28795289 | 0.72 | CYP3A4 (0.60) | CYP3A4TDP1 | |
| Hydrochloric Acid SCHEMBL4493507 | 0.72 | AURKA (0.54) | EGFRKDRAURKBAURKA | |
| SCHEMBL6182709 | 0.70 | KIT (0.59) | KITEGFRKDRRETENPP1 | |
| SCHEMBL15504611 | 0.69 | KIT (1.00) | KITEGFRKDRRETAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1885719-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006066795-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-06-29 | — | — | WO | disclosed |
| EP-1674467-A1 | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors | 4SC AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | KIT 1709/4885EGFR 437/4885KDR 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.